Esra Ergün Alış
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Esra Ergün Alış has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Venturi
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
1 shared publication - Ali Rıza Çalişkan
Department of Gastroenterology, Faculty of Medicine, Adiyaman University, Adıyaman, Turkey, Turkey (Türkiye)
1 shared publication - Ali Türeyen
Division of Gastroenterology, Eskisehir City Hospital, Eskisehir, Turkey
1 shared publication - Altay Çelebi
Department of Gastroenterology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye
1 shared publication - Anna Valeryevna Kagramanova
Loginov Moscow Clinical Scientific Center; Research Institute for Healthcare Organization and Medical Management
1 shared publication - Antonello Pietrangelo
Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, University Hospital of Modena 41125 Modena, Italy
1 shared publication
Latest Publications
- Open Access
- 17 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (10) , 2532
Early Postoperative C-Reactive Protein Trajectories After Thoracic Surgery: A Retrospective Cohort Study
Background: Distinguishing expected postoperative inflammation from early infection remains challenging after thoracic surgery; serial C-reactive protein (CRP) is widely used to aid this differentiation. Methods: We conducted a single-centre retrospective cohort study of adults undergoing thoracic surgery (1 January 2022–31 December 2024). CRP was measured preoperatively and on postoperative days (POD) 1–5; trajectories were compared by surgical approach and extent of resection using repeated-measures ANOVA with Greenhouse–Geisser correction (α = 0.05). Results: Among 144 patients (VATS n = 79; open thoracotomy n = 65; extent: segmentectomy n = 25, lobectomy n = 96, bilobectomy n = 9, pneumonectomy n = 14), overall CRP rose from 26.6 ± 45.0 mg/L preoperatively to a POD2 peak of 200.9 ± 72.7 mg/L, then declined to 118.1 ± 70.7 mg/L by POD5. Thoracotomy showed higher peaks than VATS (POD2 216.1 ± 76.0 vs. 152.3 ± 29.9 mg/L; POD3 206.7 ± 88.7 vs. 159.8 ± 72.4 mg/L), but time × approach was not statistically significant (F = 1.042, p = 0.381; partial η2 = 0.115). The extent analysis showed the highest peaks with pneumonectomy (POD2 273.7 ± 46.3 mg/L) compared with bilobectomy (155.7 ± 11.0 mg/L) and lobectomy (VATS 132.1 ± 3.7, open 196.8 ± 85.3 mg/L); time × extent was not significant (F = 1.136, p = 0.384; partial η2 = 0.299). The overall effect of time did not reach significance (F = 1.127, p = 0.352; partial η2 = 0.124), reflecting variability. Patients with clinically diagnosed infections exhibited more prolonged CRP elevation, often >100 mg/L beyond POD4, whereas uncomplicated cases declined after the POD2 peak; these trends did not achieve statistical significance in this cohort. Conclusions: Early postoperative CRP in thoracic surgery typically peaks at 48–72 h and then falls. Higher peaks with open surgery and more extensive resection were observed but not statistically confirmed; persistence > 100 mg/L after POD3–4 may flag complications. Prospective studies are needed to validate thresholds and refine CRP-based surveillance pathways.
- 17 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (10) , 2532
Open AccessEarly Postoperative C-Reactive Protein Trajectories After Thoracic Surgery: A Retrospective Cohort Study
Background: Distinguishing expected postoperative inflammation from early infection remains challenging after thoracic surgery; serial C-reactive protein (CRP) is widely used to aid this differentiation. Methods: We conducted a single-centre retrospective cohort study of adults undergoing thoracic surgery (1 January 2022–31 December 2024). CRP was measured preoperatively and on postoperative days (POD) 1–5; trajectories were compared by surgical approach and extent of resection using repeated-measures ANOVA with Greenhouse–Geisser correction (α = 0.05). Results: Among 144 patients (VATS n = 79; open thoracotomy n = 65; extent: segmentectomy n = 25, lobectomy n = 96, bilobectomy n = 9, pneumonectomy n = 14), overall CRP rose from 26.6 ± 45.0 mg/L preoperatively to a POD2 peak of 200.9 ± 72.7 mg/L, then declined to 118.1 ± 70.7 mg/L by POD5. Thoracotomy showed higher peaks than VATS (POD2 216.1 ± 76.0 vs. 152.3 ± 29.9 mg/L; POD3 206.7 ± 88.7 vs. 159.8 ± 72.4 mg/L), but time × approach was not statistically significant (F = 1.042, p = 0.381; partial η2 = 0.115). The extent analysis showed the highest peaks with pneumonectomy (POD2 273.7 ± 46.3 mg/L) compared with bilobectomy (155.7 ± 11.0 mg/L) and lobectomy (VATS 132.1 ± 3.7, open 196.8 ± 85.3 mg/L); time × extent was not significant (F = 1.136, p = 0.384; partial η2 = 0.299). The overall effect of time did not reach significance (F = 1.127, p = 0.352; partial η2 = 0.124), reflecting variability. Patients with clinically diagnosed infections exhibited more prolonged CRP elevation, often >100 mg/L beyond POD4, whereas uncomplicated cases declined after the POD2 peak; these trends did not achieve statistical significance in this cohort. Conclusions: Early postoperative CRP in thoracic surgery typically peaks at 48–72 h and then falls. Higher peaks with open surgery and more extensive resection were observed but not statistically confirmed; persistence > 100 mg/L after POD3–4 may flag complications. Prospective studies are needed to validate thresholds and refine CRP-based surveillance pathways.
- 9 April 2025
- Published by Taylor & Francis in Occupational Therapy In Health Care
- p. 1-17
Exercise Capacity and Occupational Competence Sequelae in COVID-19 Survivors: A Longitudinal Study
The Sars-Cov-2 infection disease (COVID-19) causes symptoms during both acute and post-COVID phases. This study assessed exercise capacity and occupational competence of 20 hospitalized COVID-19 patients, at discharge and three months later using the 6-Minute Step Test and Occupational Self-Assessment. Significant differences were found in both exercise capacity and occupational competence scores between discharge and three months later (p < 0.05). However, these measurements were not correlated (p > 0.05). Although patients show improvement after discharge, some symptoms persisted, affecting their exercise, and occupational performance. Further research is needed to explore long-term occupational outcomes of COVID-19 beyond one year.
- 9 April 2025
- Published by Taylor & Francis in Occupational Therapy In Health Care
- p. 1-17
Exercise Capacity and Occupational Competence Sequelae in COVID-19 Survivors: A Longitudinal Study
The Sars-Cov-2 infection disease (COVID-19) causes symptoms during both acute and post-COVID phases. This study assessed exercise capacity and occupational competence of 20 hospitalized COVID-19 patients, at discharge and three months later using the 6-Minute Step Test and Occupational Self-Assessment. Significant differences were found in both exercise capacity and occupational competence scores between discharge and three months later (p < 0.05). However, these measurements were not correlated (p > 0.05). Although patients show improvement after discharge, some symptoms persisted, affecting their exercise, and occupational performance. Further research is needed to explore long-term occupational outcomes of COVID-19 beyond one year.
- Open Access
- 9 November 2021
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (1) , 147-157
Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study
INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID−) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.
- 9 November 2021
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (1) , 147-157
Open AccessPrevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study
INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID−) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection.
- Open Access
Assessment of the Relationship between Mortality and Troponin I Levels in Hospitalized Patients with the Novel Coronavirus (COVID-19)
Background and Objectives: This study aimed to evaluate the relationship between mortality and cardiac laboratory findings in patients who were hospitalized after a positive PCR for COVID-19 infection. Materials and Methods: This study included patients who were admitted to or referred to the hospital between 20 March and 20 June 2020, diagnosed with COVID-19 via a positive RT-PCR from nasal and pharyngeal swab samples. The troponin I level was measured from each patient. Medical records of patients were retrospectively reviewed and analyzed. Results: A hundred and five patients who were diagnosed with COVID-19 and hospitalized, or who died in the hospital due to COVID-19, were included in this study. There was a statistically significant difference between the troponin I high and low level groups in terms of age (years), BMI, shortness of breath (SB), oxygen saturation (%), hypertension, length of stay in the ICU; and for mortality, C-reactive protein, the neutrophil-to-lymphocyte ratio, hemoglobin, lactate dehydrogenase, ferritin, D-dimer, creatine kinase-MB, prothrombin time, calcium, and 25-hydroxy vitamin 25(OH)D3 (all p < 0.05). In the logistic analyses, a significant association was noted between troponin I and the adjusted risk of mortality. A ROC curve analysis identified troponin I values > 7.8 pg/mL as an effective cut-off point in mortality for patients with COVID-19. A troponin I value of higher than 7.8 pg/mL yielded a sensitivity of 78% and a specificity of 86%. Conclusions: The hospital mortality rate was higher among patients diagnosed with COVID-19 accompanied by troponin levels higher than 7.8 pg/mL. Therefore, in patients diagnosed with COVID-19, elevated troponin I levels >7.8 pg/mL can be considered an independent risk factor for mortality.
Open AccessAssessment of the Relationship between Mortality and Troponin I Levels in Hospitalized Patients with the Novel Coronavirus (COVID-19)
Background and Objectives: This study aimed to evaluate the relationship between mortality and cardiac laboratory findings in patients who were hospitalized after a positive PCR for COVID-19 infection. Materials and Methods: This study included patients who were admitted to or referred to the hospital between 20 March and 20 June 2020, diagnosed with COVID-19 via a positive RT-PCR from nasal and pharyngeal swab samples. The troponin I level was measured from each patient. Medical records of patients were retrospectively reviewed and analyzed. Results: A hundred and five patients who were diagnosed with COVID-19 and hospitalized, or who died in the hospital due to COVID-19, were included in this study. There was a statistically significant difference between the troponin I high and low level groups in terms of age (years), BMI, shortness of breath (SB), oxygen saturation (%), hypertension, length of stay in the ICU; and for mortality, C-reactive protein, the neutrophil-to-lymphocyte ratio, hemoglobin, lactate dehydrogenase, ferritin, D-dimer, creatine kinase-MB, prothrombin time, calcium, and 25-hydroxy vitamin 25(OH)D3 (all p < 0.05). In the logistic analyses, a significant association was noted between troponin I and the adjusted risk of mortality. A ROC curve analysis identified troponin I values > 7.8 pg/mL as an effective cut-off point in mortality for patients with COVID-19. A troponin I value of higher than 7.8 pg/mL yielded a sensitivity of 78% and a specificity of 86%. Conclusions: The hospital mortality rate was higher among patients diagnosed with COVID-19 accompanied by troponin levels higher than 7.8 pg/mL. Therefore, in patients diagnosed with COVID-19, elevated troponin I levels >7.8 pg/mL can be considered an independent risk factor for mortality.
- 6 May 2011
- Published by Springer Nature in International Urology and Nephrology
- Vol. 44 (1) , 19-27
Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatment
This study aims to scrutinize the hospitalized patients with the diagnosis of acute prostatitis after transrectal ultrasound-guided biopsy of the prostate (TRUSBP) focusing their history of previous antibiotic use, clinical pictures, microbiologic features, and resistance patterns of the isolates. A retrospective evaluation of the records between 2005 and 2010 revealed 13 patients. All patients received ciprofloxacin 500 mg twice a day starting from the day before TRUSBP for 5 days. Positive 13 urine and 7 blood samples (Escherichia coli in 12 patients, Enterococcus species in one) were evaluated for resistance patterns. All were resistant to fluoroquinolones. Extended spectrum beta-lactamase producing E. coli isolated in 4 patients were treated with carbapenems. Empirical ceftriaxone was shifted to carbapenem (4 patients), vancomycin (1 patient). Empirical carbapenem was maintained in 5 patients. Seven patients with elevated PSA received fluoroquinolones for 4 weeks before TRUSBP on the assumption that they had subclinical infectious prostatitis. Previous exposure to fluoroquinolones did not lead to important differences in respect to the studied parameters. The prompt initiation of effective treatment is essential to decrease morbidity and mortality. Empirical treatment would be a second or third generation cephalosporins, or carbapenems according to clinical severity of patients.
- 6 May 2011
- Published by Springer Nature in International Urology and Nephrology
- Vol. 44 (1) , 19-27
Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatment
This study aims to scrutinize the hospitalized patients with the diagnosis of acute prostatitis after transrectal ultrasound-guided biopsy of the prostate (TRUSBP) focusing their history of previous antibiotic use, clinical pictures, microbiologic features, and resistance patterns of the isolates. A retrospective evaluation of the records between 2005 and 2010 revealed 13 patients. All patients received ciprofloxacin 500 mg twice a day starting from the day before TRUSBP for 5 days. Positive 13 urine and 7 blood samples (Escherichia coli in 12 patients, Enterococcus species in one) were evaluated for resistance patterns. All were resistant to fluoroquinolones. Extended spectrum beta-lactamase producing E. coli isolated in 4 patients were treated with carbapenems. Empirical ceftriaxone was shifted to carbapenem (4 patients), vancomycin (1 patient). Empirical carbapenem was maintained in 5 patients. Seven patients with elevated PSA received fluoroquinolones for 4 weeks before TRUSBP on the assumption that they had subclinical infectious prostatitis. Previous exposure to fluoroquinolones did not lead to important differences in respect to the studied parameters. The prompt initiation of effective treatment is essential to decrease morbidity and mortality. Empirical treatment would be a second or third generation cephalosporins, or carbapenems according to clinical severity of patients.